JNJ News and Press, Johnson & Johnson From 06/22/24

2024-06-22 08:05:00 ET Summary FOMO is driving stock market decisions, especially with meme stocks like GameStop and high-flying AI stocks. That's why I prefer discounted dividend stocks over growth stocks, and highlight two picks that offer durable capital returns. Both names...

2024-06-22 04:45:00 ET When you invest for the long term, a good strategy is to add stocks from various industries with different growth qualities that complement each other. Dividend stocks generate one type of growth and can be a fantastic way to maximize your returns. They perform differ...

2024-06-21 07:47:27 ET More on Johnson & Johnson Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson (JNJ) Bernstein's 40th Annual Strateg...

Acquisition includes two pre-clinical bispecific antibodies targeting proven disease pathways, offering the potential to transform the treatment paradigm for patients living with atopic dermatitis and other immune-mediated diseases Johnson & Johnson (NYSE: JNJ) announced today that ...

2024-06-20 17:11:21 ET More on Johnson & Johnson Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson (JNJ) Bernstein's 40th Annual Strateg...

2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...

Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment ...

VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before. While researchers continue to search for a reason why this is happening, s...

2024-06-20 10:29:07 ET More on Johnson & Johnson Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson (JNJ) Bernstein's 40th Annual Strateg...

TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction PR Newswire TREMFYA ® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa....